文献速递细胞病理与分子病理胸部病理

肺癌症细胞学与组织学标本PD-L1免疫组化的一致性研究

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
PubMed 文献 · Cancer Cytopathol · 2018-02-05

该研究比较了56对肺癌细胞学与匹配手术标本中PD-L1免疫组化结果,发现肿瘤细胞PD-L1阳性率在两种标本间相关性中至高(Spearman r=0.69),细针穿刺标本更高(r=0.78),但免疫细胞PD-L1无相关性(r=0.14),提示细胞学肿瘤细胞PD-L1结果可靠,而免疫细胞PD-L1不应用于临床决策。

要点

  • 细胞学标本肿瘤细胞PD-L1与手术标本相关性中至高(r=0.69)。
  • 细针穿刺细胞学标本肿瘤细胞PD-L1相关性更高(r=0.78)。
  • 细胞学免疫细胞PD-L1与手术标本无相关性,不可用于临床决策。

核心结论

  • 细胞学标本肿瘤细胞PD-L1免疫组化与匹配手术标本结果相关性中至高,但免疫细胞PD-L1结果不反映手术标本,不应指导临床决策。

研究设计与样本

  • 2013至2016年收集56对细胞学标本及匹配手术标本,用抗PD-L1染色,由2名病理医生评分肿瘤细胞和免疫细胞膜阳性百分比并比较。

主要发现

  • 手术标本肿瘤细胞平均PD-L1阳性率为28%(标准差37%),免疫细胞为5%(标准差7%)。
  • 细胞学标本肿瘤细胞平均PD-L1阳性率为21%(标准差33%),免疫细胞为8%(标准差15%)。
  • 肿瘤细胞观察者间一致性高,手术和细胞学标本组内相关系数均为0.96。
  • 免疫细胞观察者间一致性中等,手术和细胞学标本组内相关系数分别为0.47和0.67。
  • 肿瘤细胞PD-L1在手术与细胞学标本间Spearman相关系数为0.69,细针穿刺标本为0.78;免疫细胞分别为0.14和0.23。

临床怎么用

  • 细胞学标本可用于评估肿瘤细胞PD-L1以辅助免疫治疗选择。
  • 细胞学标本中免疫细胞PD-L1结果不应作为临床决策依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed cell death protein 1 inhibitors increasingly are being used to treat patients with advanced lung carcinomas. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) in tumor cells (TCs) and tumor-infiltrating immune cells (ICs) is used to select patients for programmed cell death protein 1 inhibition, but few studies have evaluated PD-L1 IHC in cytology specimens. The objective of the current study was to compare PD-L1 IHC in cytology cell blocks and matched surgical specimens. METHODS: A total of 56 cytology specimens obtained between 2013 and 2016 with matching surgical specimens were stained with anti-PD-L1. Membranous positivity was scored as a percentage of the TCs and ICs by 2 pathologists. Results were compared between cytology and surgical specimens, and interobserver concordance was assessed. RESULTS: The average PD-L1 positivity rate was 28% in TCs and 5% in ICs in surgical specimens (standard deviations of 37% and 7%, respectively), and 21% in TCs and 8% in ICs in cytology specimens (standard deviations of 33% and 15%, respectively). Interobserver concordance was high for TCs in surgical and cytology specimens (intraclass correlation coefficients of 0.96 and 0.96, respectively), and was moderate for ICs in surgical and cytology specimens (intraclass correlation coefficients of 0.47 and 0.67, respectively). There was moderate to high correlation between PD-L1 positivity in TCs between surgical and cytology specimens (Spearman correlation coefficient [Spearman r], 0.69), particularly among fine-needle aspiration specimens (Spearman r, 0.78), but not between PD-L1 positivity in ICs in surgical and cytology specimens (Spearman r, 0.14), including among fine-needle aspiration specimens (Spearman r, 0.23). CONCLUSIONS: Tumor PD-L1 IHC positivity in cytology specimens appears to correlate strongly with results obtained from matching surgical specimens. PD-L1 IHC in ICs within cytology specimens does not reflect results in matched surgical specimens and should not be used in clinical decision making. Cancer Cytopathol 2018;126:253-63. © 2018 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Russell-Goldman E, Kravets S, Dahlberg SE, et al. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018. PMID: 29405663. doi:10.1002/cncy.21973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。